Menorrhagia treatment Phase III trial completed:
This article was originally published in Clinica
BEI Medical Systems has finished treating all patients involved in a US Phase III trial of its Hydro ThermAblator system for the treatment of excessive uterine bleeding, or menorrhagia. The 276-patient trial compared the safety and efficacy of the system with roller ball ablation, one of the current treatments for the condition. The Teterboro, New Jersey-based company, which plans to follow the patients for a year before filing a pre-market approval application with the FDA, will submit a six-month, interim patient follow-up analysis to the agency during the first quarter of 2000.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.